Physician profile
Alan J Gordon
NPI 1518959287
$85,963.61
in general payments reported to CMS, 2019-2025
19 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,325 · 2020: $3,519 · 2021: $15K · 2022: $10K · 2023: $334 · 2024: $51K · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $50K · Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $50,000.00 |
| Food and Beverage | $1,412.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $82,825.07 | 2019-2024 | |
| Genentech USA, INC. | $529.40 | 2019-2025 | Vabysmo, Susvimo |
| Bausch & Lomb Americas INC. | $454.38 | 2022-2025 | Stellaris, Xipere |
| Regeneron Healthcare Solutions, INC. | $451.46 | 2019-2025 | Eylea, Eylea Hd |
| Dutch Ophthalmic, USA | $322.24 | 2019-2022 | |
| Alimera Sciences, INC. | $315.70 | 2024 | Iluvien, Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $262.38 | 2019 | |
| Allergan, INC. | $201.36 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $175.66 | 2019 | |
| Abbvie INC. | $120.61 | 2023-2025 | |
| Eyepoint US, INC. | $108.95 | 2020 | |
| Astellas Pharma US INC | $49.81 | 2024-2025 | Izervay |
| Regeneron Pharmaceuticals, INC. | $44.38 | 2022 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Apellis Pharmaceuticals, INC. | $34.18 | 2023 | Syfovre |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $29.23 | 2023 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$442,937.57 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.